LinkedIn Logo

February 20-22, 2018

Boston, USA

Speakers

Expand/Collapse

Alexandre Akoulitchev
Chief Scientific Officer and Co-Founder
Oxford BioDynamics

Day Two

Thursday, February 22nd, 2018

13.30 | Multi-Center Biomarker Development for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis

14.30 | Session Q&A Panel

Thomas Skøt Jensen
CEO & Co-founder
Intomics

Day Two

Thursday, February 22nd, 2018

09.10 | Precision Medicine in a Data-rich Era – Challenges and Successful Bioinformatics Approaches

09.30 | Session Q&A Panel

Speaker to be Confirmed

Cerveau Technologies

Day Two

Thursday, February 22nd, 2018

11.40 | Presentation to Be Confirmed

12.00 | Session Q&A Panel

Alice Zhang
CEO
Verge Genomics

Brad Margus
Co-founder & CEO
Cerevance

Brendon Boot
Medical Director
Voyager Therapeutics

Damian Crowther
Director, R&D Neuroscience IMED Biotech Unit
AstraZeneca

Day One

Wednesday, February 21, 2018

09.50 | Session Q&A Panel

09.10 | Shedding Light on the Role of TREM2 in Alzheimer’s Disease

Douglas Bonhaus
CSO
Neuropore Therapeutics

Day Two

Thursday, February 22nd, 2018

16.20 | Session Q&A Panel

16.00 | Targeting Autophagic Protein Clearance Mechanisms for the Treatment of Neurodegenerative Disease

Douglas Galasko
Professor, Department of Neurosciences
University of California, San Diego

Day Two

Thursday, February 22nd, 2018

14.30 | Session Q&A Panel

14.10 | Biomarker Data in Cerebrospinal Fluid in Parkinson’s Disease: The PPMI Study

Holly Soares
Head Translational Neuroscience
AbbVie

Day Two

Thursday, February 22nd, 2018

14.30 | Session Q&A Panel

13.50 | Utility of Neurofilament Light Chain as a Translational Tool in Neurodegenerative Disorders

Jan Torleif Pedersen
Director, TBL Alzheimers Disease and Dementia
Neurodegeneration, H. Lundbeck A/S

Day Two

Thursday, February 22nd, 2018

09.30 | Session Q&A Panel

08.50 | Development of Phospo-Tau Antibodies Targeting Pathologic Forms of Tau

Jay Schneider
Professor, Pathology, Anatomy and Cell Biology, Director, Parkinson’s Disease Research Unit
Thomas Jefferson University

Day One

Wednesday, February 21, 2018

16.00 | Evaluating Translatability: Relevance of Rodent & Nonhuman Primate Preclinical Models of Cognitive Impairment to Clinical Drug Development

16.40 | Session Q&A Panel

Johan Luthman
Vice President, Neuroscience Business Group
Eisai Pharmaceuticals

Day Two

Thursday, February 22nd, 2018

12.00 | Session Q&A Panel

11.00 | Perspectives on Biomarker Applications Through Drug Development

Jonathan Brotchie
Co-Founder and Chairman
Atuka Inc.

Day One

Wednesday, February 21, 2018

16.40 | Session Q&A Panel

16.20 | Translational Value of Non-Human Primate Models of Motor Impairment and Disease Progression in Parkinson’s Disease

Jonathan Levenson
Senior Director, Preclinical Research & Development
Proclara Biosciences

Day Two

Thursday, February 22nd, 2018

16.20 | Session Q&A Panel

15.20 | Developing Preclinical Biomarkers of Proteopathic Seeds in Neurodegenerative Disease

Krzysztof Wicher
Principal Scientist and Group Leader
Ossianix

Larry Brown
Executive Vice President R&D, Chief Scientific Officer
Noveome Biotherapeutics

Martin Tolar
Founder, President & CEO
Alzheon, Inc

Day Two

Thursday, February 22nd, 2018

09.30 | Session Q&A Panel

08.30 | The Amyloid Cascade Hypothesis: The Path Forward in Developing Targeted Therapies for Alzheimer’s Disease

Massimiliano Bianchi
General Manager & Scientific Director
Transpharmation Ltd

Day One

Wednesday, February 21, 2018

09.50 | Session Q&A Panel

09.30 | The Importance of Microtubular Proteins & Cytokines in Neuroplasticity & Neuroinflammation

Ottavio Vitolo
VP Clinical Development
Homology Medicines Inc

Workshop A

Tuesday, February 20

08.00 | Exploring the Application of Gene Editing in the Treatment of CNS Disorders

Patrice Garnier
CEO
Amabiotics

Workshop C

Tuesday, February 20

15.00 | The Gut-Brain Axis: The Microbiome as a Versatile Target for Neurodegenerative Disease

Richard Ransohoff
Previously VP & Senior Research Fellow Neuroimmunology (Biogen)
Harvard Medical School

Day One

Wednesday, February 21, 2018

09.50 | Session Q&A Panel

08.30 | (Re) Introduction to Microglia as Intrinsic Brain Cells

Richard Wade-Martins
Professor Molecular Neuroscience
University of Oxford

Robert Bell
Associate Research Fellow, Translational Gene Therapy
Pfizer

S. Pablo Sardi
R&D Director
Sanofi-Genzyme

Day Two

Thursday, February 22nd, 2018

16.20 | Session Q&A Panel

15.40 | The Role of GBA in Lysosomal Function, Neuroprotection and Progression in Parkinson’s Disease

Samuel Hasson
Principal Investigator, Neuroscience
Pfizer

Workshop B

Tuesday, February 20

11.30 | The Promise & Challenge of Neuroimmune Therapeutics: Targets, Models, and the Science Behind the Innate Immune System’s Role in Neurodegenerative Disease

Susan Browne
Director
Teva Pharmaceuticals

Tamara Maes
CSO and VP
Oryzon Genomics S.A

Tarek Samad
Head, Neurodegeneration
Pfizer

Day One

Wednesday, February 21, 2018

09.50 | Session Q&A Panel

08.50 | Targeting Innate and Adaptive Immune Mechanisms to Modulate Neurodegeneration

Ping Chiao
Senior Director
Biogen

Day Two

Thursday, February 22nd, 2018

12.00 | Session Q&A Panel

11.20 | Amyloid PET Imaging in Aducanumab Ph1b PRIME study